- The two-arm Phase 2a study is expected to enroll 20 first-recurrent GBM patients to receive VBI’s cancer vaccine candidate, VBI-1901, in combination with either GM-CSF or AS01B
- Initial immunologic data from the VBI-1901 with AS01B study arm expected Q4 2020
- Expanded immunologic data, tumor and clinical responses from VBI-1901 with GM-CSF study arm expected Q2 2020
- VBI is the first biopharma company to collaborate with GSK to assess the AS01B adjuvant system as part of a therapeutic cancer vaccine candidate
Catalyst
Slingshot members are tracking this event:
VBI Vaccines (VBIV) Announces Dosing of First Recurrent GBM Patient in Phase 2a Study of Cancer Vaccine Candidate, VBI-1901, in Combination with GSK’s AS01B Adjuvant System
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| VBIV |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 02, 2020
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Vbi-1901, Phase 2a, Cancer Vaccine, As01b
